Posaconazole Intravenous (Iv) Solution Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) solution
Available Strengths: 300 mg/100 mL
Reference Brands: Noxafil(US & EU)
Category:
Anti-fungal
Posaconazole IV inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane formation. It provides broad-spectrum antifungal activity, rapid systemic absorption, and excellent tissue penetration. Benefits include effective treatment of invasive fungal infections, reliable intravenous delivery, and high bioavailability, crucial for managing severe fungal diseases.
Posaconazole Intravenous (IV) Solution is available in Intravenous (IV) solution
and strengths such as 300 mg/100 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Posaconazole Intravenous (IV) Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Posaconazole Intravenous (IV) Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Posaconazole IV is approved in the EU and US for treating invasive fungal infections. In the EU, MSD’s Noxafil IV is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continued safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We support efficient market access for posaconazole IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing